The Thai Journal of Pharmaceutical Sciences
Abstract
The unprecedented challenges presented by COVID-19 pandemic demands for an urgent development of effective therapeutic strategies against the deadly virus. Researchers thus far have revealed outcomes of pre-clinical and clinical studies of different interventions. This study aims to present overall summary of therapeutics that until this date are reported for their efficacy against COVID-19 in pre-clinical and clinical trials. A thorough literature search was conducted using databases for identification of studies published on the severe acute respiratory syndrome CoV (SARS COV-2) treatment. According to pre-clinical experiments, Nefamostat mesylate, Remdesivir, Chloroquine (CQ), Hydroxychloroquine (HCQ), β-D-N4-hydroxycytidine (NHC EIDD-1931), Ivermectin, Boceprevir, Calpain inhibitors, GC 376, Teicoplanin, Nelfinavir, Saquinavir, Alprostadil, and Interferons (IFNs) showed maximum SARS CoV-2 inhibition. Among clinical trials the Corticosteroids, Lopinavir/Ritonavir, CQ, and HCQ presented adverse effects while Remdesivir, Favipiravir, Tocilizumab, IFNs, Lenzilumab, dexamethasone, arbidol, and Convalescent plasma were featured with potential benefits and warranting further investigation. Based on these results, COVID-19 treatments remain investigational with an urgent need of well-structured efforts towards drugs development, evaluation, and analysis.
Publisher
Faculty of Pharmaceutical Sciences, Chulalongkorn University
First Page
490
Last Page
504
Recommended Citation
Bibi, Maryam; Sadia, Aatika; Shahzad, Muhammad; Irfan, Ahmad; and Raza Basra, Muhammad Asim
(2022)
"Efficacy of investigative candidate drugs against SARS CoV-2: An update on pre-clinical and clinical trials,"
The Thai Journal of Pharmaceutical Sciences: Vol. 46:
Iss.
5, Article 2.
Available at:
https://digital.car.chula.ac.th/tjps/vol46/iss5/2